Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

ABSTRACT: The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues

SUBMITTER: Navarro D 

PROVIDER: S-EPMC9104141 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature